Aug. 8 at 2:21 PM
$LLY plunges 14% on disappointing weight-loss pill data despite crushing Q2 earnings! 📉
Eli Lilly beat both top and bottom line estimates, with a 61% EPS jump and a 38% revenue surge. Yet, disappointing weight-loss pill data overshadowed its strong performance and raised FY outlook.
Is this a buying opportunity? Check the ETFs like
$IHE,
$PPH,
$OZEM with big LLY exposure here 👉 https://www.zacks.com/stock/news/2684363/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?cid=sm-stocktwits-2-2684363-body-6878&ADID=SYND_STOCKTWITS_TWEET_2_2684363_BODY_6878